In this episode, Dr. Orkin discusses results from key studies reported at AIDS 2020: Virtual, with new data on the following hot topics: current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention. The overview includes:
- The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF
- A pooled analysis of randomized trials evaluating a switch to BIC/FTC/TAF in patients 65 years of age or older with virologic suppression on their current ART
- A Kaiser Permanente study of BMI changes over time following ART initiation
- An analysis of the longitudinal prospective OPERA cohort that assessed weight change with switch from TDF to TAF
- Metabolic changes with switch from 3- or 4-drug TAF-based ART to 2-drug DTG/3TC in the TANGO study
- Updated findings from the Tsepamo birth surveillance study in Botswana evaluating the prevalence of neural tube defects by antiretroviral exposure during conception/pregnancy
- A retrospective study of COVID-19 in people with HIV presenting at 5 New York City Emergency Departments from March 2 to April 15, 2020
- An analysis of protocol-defined virologic failure in the P011 study comparing islatravir plus DOR vs DOR/3TC/TDF in treatment-naive adults
- A study evaluating the lenacapavir pharmacokinetic profile
- Results from the HPTN 083 trial investigating the efficacy and safety of long-acting injectable cabotegravir vs daily oral TDF/FTC for PrEP in MSM and TGW
Presenter:
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Content based on a CME program supported by independent educational grants from Gilead Sciences, Merck Sharp & Dohme Corp., and ViiV Healthcare.
Link to full program: https://bit.ly/33YRz0t
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
